Abstract
On rat cortical slices, cyclothiazide, 1-100 microM, (ED50 = 7.1 +/- 1.1 microM) enhanced the depolarizing action of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA) but not that of N-methyl-D-aspartate (NMDA). Cyclothiazide 10 microM also reversed the action of a 2,3-benzodiazepine, GYKI 53655, which is a non-competitive AMPA receptor antagonist, but not that of the quinoxalinedione, NBQX, which is a competitive AMPA receptor antagonist.
MeSH terms
-
Animals
-
Benzodiazepines / antagonists & inhibitors*
-
Benzodiazepines / pharmacology
-
Benzothiadiazines / pharmacology*
-
Cerebral Cortex / drug effects
-
Cerebral Cortex / metabolism
-
Diuretics
-
Excitatory Amino Acid Antagonists*
-
Ibotenic Acid / analogs & derivatives
-
Ibotenic Acid / pharmacology
-
In Vitro Techniques
-
Kainic Acid / pharmacology
-
N-Methylaspartate / pharmacology
-
Quinoxalines / pharmacology
-
Rats
-
Receptors, AMPA
-
Sodium Chloride Symporter Inhibitors / pharmacology*
-
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid
Substances
-
Benzothiadiazines
-
Diuretics
-
Excitatory Amino Acid Antagonists
-
Quinoxalines
-
Receptors, AMPA
-
Sodium Chloride Symporter Inhibitors
-
2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline
-
Benzodiazepines
-
GYKI 53655
-
Ibotenic Acid
-
N-Methylaspartate
-
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid
-
cyclothiazide
-
Kainic Acid